SCHEMBL6860384

SCHEMBL6860384

N[C@@H](Cc1ccc(O)cc1)C(=O)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.54
TAAR1 Q96RJ0 3/20 0.46
SLC6A2 P23975 1/20 0.46
HDAC8 Q9BY41 2/20 0.46
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
OPRD1 P41143 1/20 0.43
LNPEP Q9UIQ6 3/20 0.41
ERAP2 Q6P179 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8990136 0.86 ALPI (0.54) SLC7A5TAAR1SLC6A2HDAC8
SCHEMBL8990144 0.86 ALPI (0.54) SLC7A5TAAR1SLC6A2HDAC8
Hydrochloric Acid SCHEMBL3050574 0.85 ALPI (0.53) SLC7A5HDAC8
Trifluoroacetic Acid SCHEMBL3051051 0.81 ALPI (0.49) SLC7A5HDAC8
SCHEMBL27337471 0.79 SLC7A5 (0.62) SLC7A5TAAR1SLC6A2HDAC8ESR1
Tyrosine Methyl Ester SCHEMBL313051 0.79 ESR1 (0.63) SLC7A5TAAR1SLC6A2ESR1ESR2
Tyrosine Methyl Ester SCHEMBL314923 0.79 ESR1 (0.63) SLC7A5TAAR1SLC6A2ESR1ESR2
Tyrosine Methyl Ester SCHEMBL1255129 0.79 ESR1 (0.63) SLC7A5TAAR1SLC6A2ESR1ESR2
SCHEMBL27680265 0.79 SLC7A5 (0.67) SLC7A5TAAR1SLC6A2HDAC8ESR1
SCHEMBL4453960 0.79 SLC7A5 (0.67) SLC7A5TAAR1SLC6A2HDAC8ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116829949-A Compositions for detecting or measuring analytes 伯蒂斯有限公司 2023-09-29 CN disclosed
US-6794490-B2 PEPTIDES FOR USE IN PREVENTION OF INFECTIONS; BACTERICIDES; MICROBIOCIDES CUBIST PHARMACEUTICALS, INC. 2004-09-21 US disclosed
EP-1240182-A2 DAPTOMYCIN ANALOGS AND THEIR USE AS ANTIBACTERIAL AGENTS Cubist Pharmaceuticals, Inc. (US) 2002-09-18 EP disclosed
US-20020058785-A1 Novel lipopeptides as antibacterial agents MERCK SHARP & DOHME CORP. 2002-05-16 US disclosed
WO-2001044271-A2 DAPTOMYCIN ANALOGS AND THEIR USE AS ANTIBACTERIAL AGENTS CUBIST PHARMACEUTICALS, INC. (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020058785-A1 Novel lipopeptides as antibacterial agents CLPTM1, NGLY1, VIP SLC7A5 3306/4885TAAR1 4451/4885SLC6A2 4850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.